false 0001314102 0001314102 2020-08-12 2020-08-12












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 12, 2020



EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)




Delaware   000-51122   26-2774444

(State or Other Jurisdiction

of Incorporation)



File Number)


(I.R.S. Employer

Identification No.)

480 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of

each class





Name of each exchange

on which registered

Common Stock, par value $0.001   EYPT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 8.01

Other Events.

On July 13, 2020, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the appointment of Dr. Jay Duker as the Company’s Chief Strategic Scientific Officer. In connection with his appointment, the Company granted Dr. Duker an option to purchase an aggregate of 250,000 shares of the Company’s common stock, par value $0.001 (the “Duker Grant”). As a result of a scrivener’s error, the press release inadvertently stated that the Duker Grant was an inducement grant outside of the Company’s 2016 Long-Term Incentive Plan (the “2016 Plan”) made in accordance with Nasdaq Listing Rule 5635(c)(4). The Duker Grant was not an inducement grant and was made pursuant to the 2016 Plan.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 12, 2020     By:  

/s/ George Elston

    Name:   George Elston
    Title   Chief Financial Officer and Head of Corporate Development